Fundraising FoxLatterell Venture Partners — Full Portfolio
29 tracked investments · listed companies and verified rows first
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Co-investorsBand of AngelsHealthCapKaiser Permanente VenturesKleiner PerkinsMontreux Equity PartnersAlly Bridge Group
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalOUP (Osage University Partners)Agent CapitalBain Capital+3 more
Evoke Pharma develops treatments for gastrointestinal disorders, focusing on advancing and commercializing GIMOTI, a nasal spray formulation for diabetic gastroparesis.
BiotechHealthtechMedical Devices
Cam L. Garner(Co-founder and Chairman)Matthew J. D'Onofrio(Co-founder & Chief Executive Officer)
Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.
Co-investorsMPM BioImpactOrbiMedThe Vertical GroupVersant Ventures
Developed lightweight portable oxygen concentrators; acquired by ResMed.
HealthtechAustin, US
John B. Rush(Executive Officer, Director)Daniel Jensen(Executive Officer)
BoardGeoff Pardo(Director)inStephen M. Salmon(Director)Richard Lin(Director)Roderick A. Young(Director)
Co-investorsGilde Healthcare
Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.
BiotechHardwareMedical Devices
Co-investorsIn-Q-TelQuestMark Partners
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalEcoR1 CapitalSofinnova VenturesAdams Street Partners
Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease.
BiotechHealthtech
Co-investorsThe Vertical Group
Mountain View, US
Alan Jacobs(Executive Officer, Director)Jennifer Jacobs(Executive Officer, Director)
BoardJames Woody(Director)John Friedman(Director)Grace Colon(Director)Rodney Markin(Director)
Co-investorsEaston Capital
ProteinSimple developed instruments and consumables for protein analysis; acquired by Techne/Bio-Techne for $300M in 2014.
Co-investorsMitsui Global InvestmentThe Vertical Group
Developing cancer therapeutics based on apoptosis research; IPO'd December 2013.
Transcend Medical was a Menlo Park, CA medical-device company spun out of ForSight Labs that developed the CyPass Micro-Stent, a minimally invasive glaucoma implant to reduce intraocular pressure.
Menlo Park, US
Co-investorsCanaan PartnersLightstone Ventures
Viracta Therapeutics was a precision oncology company.
BiotechHealthtechCardiff, US
James Woody(Director)David Slack(Executive Officer)
BoardIvor Royston(Executive Officer, Director)Patrick Soon-Shiong(Director)Richard Ghalie(Director)
Co-investorsAisling CapitalaMoonVirtus Inspire Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CalistogaCellective TherapeuticsEnsure MedicalEvokeMeritageMeritage PharmaOncoMedOncoMed PharmaceuticalsPathwayPathway MedicalPetrolix WebsiteProteolixRevascular TherapeuticsTranscend
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.